Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.

@article{Kneteman2006AntiHCVTI,
  title={Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.},
  author={Norman Mark Kneteman and Amy J. Weiner and John O'Connell and Marc S. Collett and Tiejun Gao and Lea Aukerman and Rosemary Kovelsky and Zhi-Jie Ni and Qing Zhu and Ahmad Hashash and Janine Kline and Belinda Hsi and Daniel E. Schiller and Donna Douglas and D. Lorne Tyrrell and David F. Mercer},
  journal={Hepatology},
  year={2006},
  volume={43 6},
  pages={1346-53}
}
Compounds with in vitro anti-hepatitis C virus (HCV) activity are often advanced directly into clinical trials with limited or no in vivo efficacy data. This limits prediction of clinical efficacy of compounds in the HCV drug pipeline, and may expose human subjects to unnecessary treatment effects. The scid-Alb-uPA mouse supports proliferation of transplanted human hepatocytes and subsequent HCV infection. Cohorts of genotype 1a HCV-infected mice were treated with interferon alpha-2b(IFN-alpha… CONTINUE READING
44 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 44 extracted citations

Similar Papers

Loading similar papers…